FindTrial
Sign In

ABT-450

DRUG10 trials

Sponsors

AbbVie, Abbott, AbbVie (prior sponsor, Abbott)

Conditions

Chronic Hepatitis CChronic Hepatitis C InfectionHCVHCV InfectionHealthyHepatitis CHepatitis C (HCV)Hepatitis C Genotype 1

Phase 1

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1
CompletedNCT00850044
AbbVieHCV Infection
Start: 2009-02-28Updated: 2017-11-20
Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
CompletedNCT00909311
AbbottHCV Infection
Start: 2009-05-31Updated: 2010-10-13
Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
CompletedNCT00931281
AbbottHCV Infection
Start: 2009-06-30Updated: 2010-10-13
Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450
CompletedNCT01091649
AbbottHealthy
Start: 2010-02-28End: 2010-04-30Updated: 2010-12-21

Phase 2

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
CompletedNCT01074008
AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection, HCV, Hepatitis C +1
Start: 2010-03-31End: 2012-01-31Updated: 2015-01-08
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
CompletedNCT01221298
AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection, HCV, Hepatitis C +1
Start: 2010-10-31End: 2012-04-30Updated: 2015-01-08
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
CompletedNCT01306617
AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus
Start: 2011-02-28End: 2012-10-31Updated: 2015-01-08
A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
CompletedNCT01458535
AbbVie (prior sponsor, Abbott)Hepatitis C Virus
Start: 2011-09-30End: 2013-05-31Updated: 2016-07-11
ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
CompletedNCT01464827
AbbVie (prior sponsor, Abbott)Chronic Hepatitis C, Hepatitis C Genotype 1, Hepatitis C (HCV)
Start: 2011-10-31End: 2013-09-30Updated: 2015-04-22
Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects
CompletedNCT01563536
AbbVie (prior sponsor, Abbott)Chronic Hepatitis C Infection
Start: 2012-02-29End: 2013-06-30Updated: 2018-07-02

Related Papers

Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.
2016-02-2423 citations
Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
Antimicrobial Agents and Chemotherapy2015-06-2395 citations
<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450
Antimicrobial Agents and Chemotherapy2014-12-02116 citations
Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
New England Journal of Medicine2014-01-15256 citations
Exploratory study of oral combination antiviral therapy for hepatitis C.
2013-01-01225 citations